Calidi Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Calidi Biotherapeutics
CLDI Stock   0.83  0.03  3.49%   
Calidi Biotherapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Calidi Biotherapeutics' valuation are provided below:
Gross Profit
31 K
Market Capitalization
6.2 M
Enterprise Value Revenue
49.4238
Earnings Share
0.36
We have found one hundred twenty available fundamental signals for Calidi Biotherapeutics, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of Calidi Biotherapeutics prevailing fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 26.5 M. Enterprise Value is estimated to decrease to about 32.1 M
Check Calidi Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Calidi Biotherapeutics' main balance sheet or income statement drivers, such as Tax Provision of 13.6 K, Depreciation And Amortization of 1.9 M or Interest Expense of 1.2 M, as well as many indicators such as Price To Sales Ratio of 1 K, Dividend Yield of 0.14 or PTB Ratio of 5.65. Calidi financial statements analysis is a perfect complement when working with Calidi Biotherapeutics Valuation or Volatility modules.
  
Build AI portfolio with Calidi Stock
Check out the analysis of Calidi Biotherapeutics Correlation against competitors.
For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.

Calidi Biotherapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets17.1 M16.3 M4.9 M
Slightly volatile
Short and Long Term Debt Total5.9 M6.3 M9.8 M
Slightly volatile
Other Current Liabilities2.5 M2.7 M5.9 M
Slightly volatile
Total Current Liabilities15.6 M8.5 M12.4 M
Slightly volatile
Property Plant And Equipment Net2.3 M3.4 M1.4 M
Slightly volatile
Accounts Payable1.9 M2.4 M1.2 M
Slightly volatile
Cash11.6 M11 M2.4 M
Slightly volatile
Non Current Assets Total3 M4.5 M2 M
Slightly volatile
Non Currrent Assets Other537.2 K1 M597.9 K
Very volatile
Other Assets491.7 K833.8 K604.5 K
Very volatile
Long Term Debt513 K540 K4.6 M
Slightly volatile
Cash And Short Term Investments11.6 M11 M2.4 M
Slightly volatile
Common Stock Shares Outstanding655 K598 K2.1 M
Slightly volatile
Liabilities And Stockholders Equity17.1 M16.3 M4.9 M
Slightly volatile
Non Current Liabilities Total2.3 M2.4 M11.5 M
Slightly volatile
Capital Lease Obligations1.9 M3.7 M1.1 M
Slightly volatile
Other Current Assets580.8 K731.4 K287.2 K
Slightly volatile
Other Stockholder Equity148.9 M141.8 M39.4 M
Slightly volatile
Total Liabilities21.4 M11 M24.1 M
Pretty Stable
Deferred Long Term Liabilities492.8 K554.4 K605.1 K
Slightly volatile
Property Plant And Equipment Gross3.3 M5.9 M2 M
Slightly volatile
Short and Long Term Debt3.1 M2.9 M4.4 M
Slightly volatile
Total Current Assets12.3 M11.8 M2.8 M
Slightly volatile
Capital Stock2.6 K2.3 K2.2 K
Slightly volatile
Short Term Debt3.6 M4 M4.9 M
Slightly volatile
Common Stock2.6 K2.3 K2.2 K
Slightly volatile
Property Plant Equipment877.8 K1.2 M819 K
Slightly volatile
Net Receivables1.6 M1.6 M349.3 K
Slightly volatile
Non Current Liabilities Other1.6 M1.8 M2 M
Slightly volatile

Calidi Biotherapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision13.6 K16.1 K7.7 K
Slightly volatile
Depreciation And Amortization1.9 M1.8 M470.8 K
Slightly volatile
Interest Expense1.2 M1.1 M562.1 K
Slightly volatile
Selling General Administrative12 M14.8 M6.9 M
Slightly volatile
Other Operating Expenses20.2 M25 M12 M
Slightly volatile
Research Development8.1 M10.2 M5.1 M
Slightly volatile
Total Operating Expenses19.8 M25 M11.9 M
Slightly volatile
Reconciled Depreciation1.9 M1.8 M473.9 K
Slightly volatile
Income Tax Expense12.3 K16.1 K7.3 K
Slightly volatile
Selling And Marketing Expenses1.6 M1.1 M3.4 M
Slightly volatile

Calidi Biotherapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings1.3 M1.7 M1.7 M
Slightly volatile
Stock Based Compensation3.6 M3.4 M1.9 M
Slightly volatile
Begin Period Cash Flow2.6 M2.5 M1.2 M
Slightly volatile
Depreciation1.9 M1.8 M520.4 K
Slightly volatile
Capital Expenditures13.7 K14.4 K301.4 K
Slightly volatile
Change To Operating Activities1.4 M2.2 M1.1 M
Slightly volatile
Total Cash From Financing Activities18.3 M31.5 M10.6 M
Slightly volatile
End Period Cash Flow11.8 M11.3 M2.5 M
Slightly volatile
Change To Netincome10 M9.5 M4 M
Slightly volatile
Dividends Paid1.3 M1.5 M1.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1 K1.7 K941
Slightly volatile
Dividend Yield0.140.160.1785
Slightly volatile
Stock Based Compensation To Revenue2.372.662.9036
Slightly volatile
Capex To Depreciation0.01140.0121.4398
Slightly volatile
EV To Sales1.1 K1.8 K977
Slightly volatile
Payables Turnover0.410.390.2123
Slightly volatile
Sales General And Administrative To Revenue334318110
Slightly volatile
Research And Ddevelopement To Revenue15214553.3093
Slightly volatile
Capex To Revenue8.998.563.0346
Slightly volatile
Cash Per Share6.9412.993.8094
Slightly volatile
Days Payables Outstanding9139612.1 K
Slightly volatile
Income Quality0.580.80.6535
Slightly volatile
Current Ratio1.020.970.2498
Slightly volatile
Capex Per Share0.02060.02170.7331
Slightly volatile
Revenue Per Share1.390.731.5654
Slightly volatile
Interest Debt Per Share10.2510.7915.6836
Slightly volatile
Debt To Assets0.540.574.4576
Slightly volatile
Price Earnings To Growth Ratio0.00550.00580.0307
Slightly volatile
Days Of Payables Outstanding9139612.1 K
Slightly volatile
Quick Ratio1.020.970.2498
Slightly volatile
Cash Ratio0.950.910.2165
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.151.0683
Very volatile
Fixed Asset Turnover0.04530.04770.5546
Slightly volatile
Debt Ratio0.540.574.4576
Slightly volatile
Price Sales Ratio1 K1.7 K941
Slightly volatile
Asset Turnover0.01890.01990.0988
Slightly volatile

Calidi Biotherapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap26.5 M27.9 M2.3 B
Slightly volatile
Enterprise Value32.1 M33.8 M2.3 B
Slightly volatile

Calidi Fundamental Market Drivers

Calidi Upcoming Events

13th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Calidi Biotherapeutics Financial Statements

Investors use fundamental indicators, such as Calidi Biotherapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Calidi Biotherapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue-4.6 M-4.4 M
Cost Of Revenue1.8 M1.9 M
Stock Based Compensation To Revenue 2.66  2.37 
Sales General And Administrative To Revenue 318.04  333.94 
Research And Ddevelopement To Revenue 145.14  152.40 
Capex To Revenue 8.56  8.99 
Revenue Per Share 0.73  1.39 
Ebit Per Revenue(591.05)(561.50)

Currently Active Assets on Macroaxis

FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
CSANCosan SA ADR
RKTRocket Companies
When determining whether Calidi Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Calidi Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Calidi Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Calidi Biotherapeutics Stock:
How To Invest In Calidi
Details
Is Calidi Stock a good investment?
Details
What is Calidi Biotherapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Calidi Biotherapeutics Correlation against competitors.
For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is there potential for Biotechnology market expansion? Will Calidi introduce new products? Factors like these will boost the valuation of Calidi Biotherapeutics. Projected growth potential of Calidi fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.36
Return On Assets
(1.20)
Understanding Calidi Biotherapeutics requires distinguishing between market price and book value, where the latter reflects Calidi's accounting equity. The concept of intrinsic value - what Calidi Biotherapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Calidi Biotherapeutics' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Calidi Biotherapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Calidi Biotherapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Calidi Biotherapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY